<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399594</url>
  </required_header>
  <id_info>
    <org_study_id>CAH 70-3402</org_study_id>
    <nct_id>NCT00399594</nct_id>
  </id_info>
  <brief_title>Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.</brief_title>
  <acronym>INCREMENTAL</acronym>
  <official_title>Investigating Non-response to Cardiac Resynchronization: Evaluation of Methods to Eliminate Non-response &amp; Target Appropriate Lead Location (INCREMENTAL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Heart Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying &amp; optimizing strategies to reduce the burden of heart failure is vital. Despite
      advances in pharmacotherapy, patients with heart failure are at high risk for death &amp;
      hospitalization. Cardiac resynchronization therapy (CRT) synchronizes ventricular mechanical
      activity, improves cardiac output &amp; reduces HF symptoms. However, ~50% of patients do not
      clearly respond to CRT. Sub-optimal placement of the LV pacing lead appears to be an
      important reason for non-response.

      This study will assess whether targeted LV lead placement will result in an increased
      probability of CRT response at 52 weeks vs. usual (lateral wall) lead placement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Identifying &amp; optimizing strategies to reduce the burden of heart failure (HF) is
      vital. Despite advances in pharmacotherapy, patients with HF are at high risk for death &amp;
      hospitalization. Over 25% of patients with systolic HF have dyssynchronous ventricular
      contraction that results in paradoxical septal motion, further impairing left ventricular
      (LV) function &amp; HF progression. Cardiac resynchronization therapy (CRT) synchronizes
      ventricular mechanical activity, improves cardiac output &amp; reduces HF symptoms. However, ~50%
      of patients do not clearly respond to CRT. Sub-optimal placement of the LV pacing lead
      appears to be an important reason for non-response.

      Screening. Mechanical synchrony is vitally important in optimizing CRT response. Patients
      will be pre-screened with echocardiograms (echo) &amp; CRT provided to only those with
      dyssynchrony. The predicted rate of CRT response in patients pre-screened for dyssynchrony is
      estimated at 65%.

      CRT response. The combined use of a valid &amp; simple measure of functional capacity with a
      reproducible measure of LV volume is optimal in identifying CRT responders. These outcomes
      will be assessed using the Specific Activity Scale &amp; radionuclide angiography (RNA),
      respectively.

      Primary hypothesis. Targeted LV lead placement will result in an increased probability of CRT
      response at 52 weeks vs. usual (lateral wall) lead placement. CRT response will be defined as
      ≥ 10% relative reduction in LV end systolic volume &amp; ≥ 1 Specific Activity Scale class
      improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in end systolic volume plus reduction in symptoms</measure>
    <time_frame>over 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure score.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form thirty six score.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Activity Scale score.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association class.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk distance.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV volumes.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide.</measure>
    <time_frame>Change over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <condition>Cardiac Pacing, Artificial</condition>
  <condition>Defibrillators</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted LV lead placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual LV lead placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>A</intervention_name>
    <description>LV lead placement in region of latest mechanical velocity (tissue doppler)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>B</intervention_name>
    <description>LV lead placement in standard (lateral / posterolateral) position.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LV EF ≤ 0.40 measured within 3 months of enrollment,

          -  SAS class 3 or 4 symptoms indicative of moderate to severe functional capacity
             limitation due to heart failure within 1 month of enrollment.

          -  Confirmed dyssynchrony on screening echo (1.1.9), &amp;

          -  On stable doses of ACE inhibitor or angiotensin II blocker &amp; a beta-blocker for ≥ 2
             months unless medically contra-indicated.

          -  Controlled heart rate if in permanent AF (resting &lt;70 &amp; maximal &lt;120).

        Exclusion Criteria:

          -  Unable or unwilling to provide informed consent,

          -  Medical condition other than heart failure likely to cause death &lt; 1 year,

          -  Cardiac transplant planned within 6 months,

          -  Known contra-indication to transvenous CRT device implant (e.g., active sepsis,
             artificial tricuspid valve, known vascular occlusion that will prevent delivery of
             leads transvenously),

          -  Clinically significant myocardial infarction within last 2 months, or

          -  Coronary bypass graft surgery ≤ 2 months or coronary angioplasty ≤ 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek V Exner, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Libin Cardiovascular Institute of Alberta, University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quebec Heart Institute</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2006</study_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Derek Exner</investigator_full_name>
    <investigator_title>Professor and Canada Research Chair in Cardiovascular Clinical Trials</investigator_title>
  </responsible_party>
  <keyword>Mechanical dyssynchrony</keyword>
  <keyword>Biventricular pacing</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

